Lead Product(s): CVXGA1
Therapeutic Area: Infections and Infectious Diseases Product Name: CVXGA1
Highest Development Status: Preclinical Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 24, 2021
Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac’s COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform.